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ABBREVIATIONS AND ACRONYMS 
TDI - Tissue Doppler imaging  
TRPG – Tricuspid regurgitation pressure gradient 
WHO - World Health Organization    
TRvelocity   maximum velocity of Tricuspid Regurgitation jet 
SPAP - Systolic pulmonary artery pressure   
PRA  - pressure in Right Atrium 
IVS – interventricular septum     
RVFw – right ventricle free wall 
TRPG – tricuspid pressure pressure gradient   
PASP – pulmonary artery systolic pressure 
RV ESA – right ventricle end systolic area 
RVEDA – right ventricle end diastolic area 
RV FAC -  right ventricle fractional area change 
IVCT – isovolumetric contraction time 
IVRT – isovolumetric relaxation time 
RVEF – right ventricle ejection fraction 
ET- ejection time 
MPI – myocardial performance index. 
PH or PAH – pulmonary arterial hypertension. 
RVSP – right ventricle systolic pressure. 
PA – pulmonary artery 
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INTRODUCTION 
 
“When you solve one difficulty, other new difficulties arise. You then try to solve 
them. You can never solve all difficulties at once” 
 
 - P.A.M.CHIRAC 
 It is this spirit of learning more about how echocardiography can be used to 
evaluate Right ventricle function in pulmonary hypertension patients, which helps us. 
With multi various etiologies causing pulmonary hypertension, making an accurate 
diagnosis, evaluating for the cause, monitoring the disease course and detecting 
complications of the disease has always been a challenge. Selecting the most appropriate 
for screening, diagnosing and monitoring the disease has been a subject of controversy.  
 Although there is no consistent and large data available in India revealing the 
exact incidence and prevalence of the disease, the increase in disease burden is certainly 
palpable and will continue to increase with time. With high mortality rates if left 
untreated and with very little treatment options in our hands, it definitely poses a 
challenge to the medical fraternity for an early diagnosis and intervention before 
complications intervene. Most common cause of death in pulmonary hypertension is right 
ventricular failure. Unfortunately most patients present to us too late for any kind of 
meaningful intervention.   
 So as physicians, it is important for us to play a critical role in the evaluation of 
the use of appropriate diagnostic procedures and therapy modalities in the early detection 
and treatment of this disease. Rigorous and expert analogues of the available data that 
document the relative benefits and risks of the procedures can produce helpful guidelines 
that improve the effectiveness of care optimize patient outcomes and favorably affect the 
overall cost of care through a focus of resources on the most effective strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
BACKGROUND 
 Pulmonary Hypertension is a distinct clinical entity characterised by sustained 
elevation in Pulmonary artery pressure leading to right ventricular failure and death. 
Abnormalities in right ventricular function are known to occur in patients with pulmonary 
arterial hypertension and be detected at an early stage by Doppler echocardiography. 
 There is not much of data available from studies conducted in India regarding 
utility of Echocardiography in studying Right ventricle function in Pulmonary 
Hypertension patients. Right ventricle (RV) dysfunction is an important element in 
determining prognosis in Pulmonary Hypertension patients. Identification of early RV 
dysfunction is of utmost clinical importance because two-thirds of the deaths in 
Pulmonary Hypertension (PH) patients are attributable to RV failure.  The essential, 
noninvasive test in the screening and evaluation of Pulmonary Hypertension (PH) is 
Doppler echocardiography. Echocardiography can help not only to estimate right 
ventricular function, but also exclude the presence of left-heart disease. Doppler 
assessments can be used to estimate the right ventricular systolic pressure (RVSP) and to 
evaluate for the presence of intracardiac shunts and other forms of congenital heart 
disease. Studies by Tei et al. have confirmed the close correlation of 
echocardiographically estimated pulmonary arterial pressure and Doppler derived right 
ventricle indices like Myocardial performance Index, with invasive measurements in 
patients with pulmonary hypertension.  
 A thorough understanding of the pertinent facts regarding pulmonary 
hypertension is absolutely necessary before treading into its complexities in treatment 
and management. The changing concepts about pulmonary hypertension mandate the 
review of the current literature of pulmonary hypertension. 
 Recently, parameters for normal pulmonary arterial systolic pressure derived by 
echo Doppler studies have been published which suggest that the upper limit of normal of 
pulmonary arterial systolic pressure in the general population may be higher than 
previously appreciated. Importantly, however, the study characterized changes based on 
age and found a modest increase in pulmonary arterial pressure with age similar to what 
exists in the systemic circulation. 
DEMOGRAPHICS 
 
 Data regarding the prognostic implications of demographic variables such as age, 
gender, and time of onset of symptoms to diagnosis are inconsistent. The National 
Institute of health (NIH) Registry was the first large-scale evaluation of prognostic factors 
in Idiopathic pulmonary hypertension (IPAH). Age, time from onset of symptoms to 
diagnosis, and gender were not predictive of survival. In a retrospective, single center, 
uncontrolled case series of 61 patients with IPAH from India, younger age was associated 
with a worse prognosis. It should be noted that this population was younger than that 
included in the NIH Registry (mean age, 24.6 ± 11.8 years as compared to 36 ± 15 years 
[± SD]). In a study that included patients with many etiologies of PAH who were treated 
with epoprostenol, older age at diagnosis indicated a worse prognosis for those above the 
median. This, however, may be confounded by the inclusion of patients with the 
scleroderma spectrum of disease who tend to be older and also had a worse prognosis. A 
national survey of IPAH was conducted in Israel and identified 44 patients with a mean 
age of 43 ± 13 years (± SD). Although they did not find age to be a prognostic variable, 
longer time of onset from symptoms to diagnosis was associated with a worse prognosis. 
 
DEFINITION OF PULMONARY HYPERTENSION 
 
 Pulmonary arterial hypertension is defined as a sustained elevation of pulmonary 
arterial systolic pressure to more than 25 mm Hg at rest or to more than 30 mm Hg with 
exercise, with a mean pulmonary-capillary wedge pressure and left ventricular end-
diastolic pressure of less than 15 mm Hg.  
 
 The pressure within the pulmonary arterial system may be increased for one of 
two reasons – increased flow or increased resistance within the pulmonary circulation, 
both of which lead to progressive and irreversible changes in the pulmonary vascular bed 
to result in chronic pulmonary hypertension.  
 
 
 
 
CLASSIFICATION AND STAGING OF PULMONARY HYPERTENSION 
 Pulmonary hypertension can occur from diverse etiologies and number of 
attempts have been made to classify the disease. The original classification, established at 
a World Health Organization (WHO) symposium in 1973, classified pulmonary 
hypertension into groups based on the known cause, i.e. secondary and defined primary 
pulmonary hypertension (PPH) as a separate entity of unknown cause. PPH was then 
classified into three histopathological patterns:  
(a) Plexogenic arteriopathy (b) recurrent thromboembolism and (c) venoocclusive 
disease.  
 In 1998, a new classification for pulmonary hypertension was developed that 
focused on the biologic expression of the disease and etiologic factors in an attempt to 
group these illnesses on the basis of clinical similarities. This classification serves as a 
useful guide to the clinician in organizing the evaluation of a patient with pulmonary 
hypertension and developing a treatment plan. 
 In 2003 the Third World Symposium updated the classification system, notably 
dropping the term "primary" altogether. They also stressed that the staging of patients 
with PH should be based on the functional capacity of the patient rather than on 
hemodynamic parameters. The World Health Organization classification system, a 
modified form of the New York Heart Association functional classification system, was 
recommended by the Symposium as the preferred staging system. The NYHA functional 
classification (NYHA-FC) has been of prognostic importance to predict survival in PH. 
Revised Clinical Classification of Pulmonary Hypertension (Venice 2003) 
 
Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic (IPAH) 
1.2. Familial (FPAH) 
1.3. Associated with (APAH): 
  1.3.1. Collagen vascular disease 
  1.3.2. Congenital systemic-to-pulmonary shunts 
  1.3.3. Portal hypertension 
  1.3.4. HIV infection 
  1.3.5. Drugs and toxins 
  1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease, 
hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, 
splenectomy) 
 
1.4 Associated with significant venous or capillary involvement 
 
  1.4.1 Pulmonary veno-occlusive disease (PVOD) 
  1.4.2 Pulmonary capillary hemangiomatosis (PCH) 
 
2. Pulmonary hypertension with left heart disease 
  2.1. Left-sided atrial or ventricular heart disease 
  2.2. Left-sided valvular heart disease 
 3. Pulmonary hypertension associated with lung disease and/or hypoxemia 
  3.1. Chronic obstructive pulmonary disease 
  3.2. Interstitial lung disease 
  3.3. Sleep-disordered breathing 
  3.4. Alveolar hypoventilation disorders 
  3.5. Chronic exposure to high altitude 
  3.6. Developmental abnormalities 
 
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease 
  4.1. Thromboembolic obstruction of proximal pulmonary arteries 
  4.2. Thromboembolic obstruction of distal pulmonary arteries 
  4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign 
material) 
 
5. Miscellaneous: 
  Sarcoidosis, histiocytosis-X, lymphangiomatosis, compression of 
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis) 
 
 
 
 The functional classification patterned after the New York Heart Association 
Functional Classification for heart disease was developed to allow comparisons of 
patients with respect to the clinical severity of the disease process.  
WHO Functional Classification of Pulmonary Hypertension 
 
Class I – Patients with pulmonary hypertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, 
chest pain  
 
Class II – Patients with pulmonary hypertension resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or 
fatigue, chest pain, or near syncope. 
 
Class III – Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity causes undue 
dyspnea or fatigue, chest pain, or near syncope. 
 
Class IV – Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms. These patients manifest signs of right heart failure. Dyspnea 
and/or fatigue may be present even at rest. Discomfort is increased by any physical 
activity. 
 NYHA-Functional classification (NYHA-FC) has been included in several studies 
of patients with PAH, and has been used in two ways in these reports: as a variable that 
might be predictive of survival in patients with PAH, and as an outcome to assess the 
impact of therapies for PAH. Because NYHA-FC relies on patient reporting of symptoms 
as an outcome, it may hold special importance for patients themselves, but it is also 
useful for clinicians trying to assess prognosis and response to therapy in patients with 
PAH.  
 NYHA-FC has been associated with improved survival in several studies, but was 
found to be a significant predictor of mortality in only four studies. The NIH cohort study 
showed that among 194 patients who received a diagnosis showed that the risk of death 
was higher among patients in NYHA-FC III or IV than among those in NYHA-FC I or II. 
The median survival time among NYHA-FC I or II patients was nearly 6 years, compared 
with 2.5 years for patients in NYHA-FC III and 6 months for patients in NYHA-FC IV. 
In a subsequent cohort study of 44 patients with IPAH, patients who were in NYHA-FC 
IV at the time of diagnosis had a significantly higher risk of death than patients in 
NYHA-FC I, II, or III. In another retrospective study of 51 patients with IPAH, patients 
in NYHA-FC III or IV had a shorter survival time than patients in NYHA-FC II. A third 
study of 91 patients with PAH, demonstrated that patients who were in NYHA-FC IV 
(compared with NYHA-FC I, II, and III patients combined) had a significantly decreased 
survival. In summary, higher NYHA-FC (III or IV) is associated with increased mortality 
both in treated and untreated patients with IPAH; in those receiving therapy, failure to 
improve NYHA-FC or deterioration in NYHA-FC, in and of itself, may be predictive of 
poor survival. 
 The initial evaluation of patients with PH should consist of testing to confirm the 
diagnosis, a search for causative disorders and complications from the disease, and a 
determination of the severity of the disease. 
EVALUATION OF A PATIENT WITH SUSPECTED PULMONARY 
HYPERTENSION 
 
Essential Evaluation Contingent Evaluation 
History and physical examination Transesophageal echo (TEE) 
Chest x-ray (CXR) Echo with bubble study 
Electrocardiogram (ECG) CT chest ± high resolution 
Pulmonary function testing(PFT) Pulmonary angiogram 
Ventilation-perfusion scan (V/Q) Arterial blood gas 
Transthoracic echo (TTE) Cardiac MRI 
Blood tests: HIV, TFTs, LFTs, ANA Blood tests: Uric acid, BNP 
Six-minute walk test (6MWD) Polysomnography 
Overnight oximetry Cardiopulmonary exercise 
Right heart catheterization (RHC) Open lung biopsy 
 
 Left-heart disease, valvular heart disease, and parenchymal lung disease deserve 
special attention during this initial period of evaluation as they are common causes of 
pulmonary arterial pressure elevation and right ventricular failure. 
 A detailed history should be taken from the patient in an attempt to define the 
severity, duration, and degree of acceleration in symptom severity. The patient should 
also be questioned about drugs of abuse, herbal medicines and supplements, and 
prescription drugs including appetite suppressants and anorexigens.  
CLINICAL FEATURES  
  
 Patients with PH usually present with nonspecific symptoms including dyspnea 
(60%), chest pain (40%), and fatigue. Symptoms are typically related to inability to 
increase cardiac output sufficiently in response to exertion and suboptimal oxygen 
transport.  The onset of right ventricular failure, manifest by a reduction in cardiac output 
and/or elevation in right atrial pressure, is usually associated with a marked clinical 
deterioration and poor prognosis. The rapidity in which this occurs in highly variable and 
is often related to the age of onset and associated conditions. Thus, patients with 
pulmonary arterial hypertension associated with congenital heart defects will more 
commonly have a slow, insidious onset of symptoms and develop right heart failure after 
decades, whereas patients with the CREST syndrome present later in life with a 
progressive downhill course.  
 Studies by Harjai et al. in 2002 indicate that right ventricle dysfunction in 
pulmonary hypertension occurs much before clinical examination can detect or ECG 
evidence of right heart abnormality surfaces. Such class of patients are the ideal 
candidates for Doppler echocardiography screening for RV dssynchrony.  
 History and physical examination should focus on signs and symptoms 
compatible with an underlying disease including collagen vascular diseases, liver disease, 
sleep apnea, thromboembolic disease, and abnormalities in thyroid function. 
 The cardiac examination may reveal signs such as an increased pulmonic 
component of the second heart sound, an early systolic ejection click, a right ventricular 
fourth heart sound, a right ventricular heave, elevation of the jugular venous pulsations, 
or a murmur of either pulmonic or tricuspid insufficiency; however, none of these 
findings is specific to PH. 
  In addition to undergoing a careful cardiac examination, the patient should be 
questioned about congenital heart disease and previous catheter ablation therapy for atrial 
fibrillation, a procedure that has been associated with pulmonary vein stenosis and PH. 
ELECTROCARDIOGRAM  
 The electrocardiogram (ECG) may be suggestive of right ventricular hypertrophy 
or right atrial enlargement and may demonstrate a right axis deviation. The sensitivity 
and specificity of the ECG for detecting PH are sufficiently poor to preclude its use as a 
screening tool; however, patients with newly diagnosed PH should have at least 1 ECG to 
establish a baseline for future comparison. 
 In a study of 51 patients with untreated IPAH, several ECG variables, including 
increased P-wave amplitude in lead II, qR pattern in lead V1, and World Health 
Organization criteria for RV hypertrophy were associated with an increased risk of death. 
The prognostic value of these factors remained even after controlling for PVR. 
 
 Although all patients with pulmonary hypertension had echocardiographic 
evidence of right ventricle dyssynchrony, there was no change in the QRS complex 
duration. 
 
CHEST X RAY 
 Right ventricular or pulmonary artery enlargement may be demonstrated on chest 
x-ray. Chest x-ray typically shows central enlargement of the pulmonary arteries with 
peripheral "pruning." Lupi and colleagues have described an index of PH based on the 
ratio of the summed horizontal measurements of the pulmonary arteries from midline to 
their first divisions, divided by the transverse diameter. Chest radiography can be 
extremely helpful in identification of coexisting conditions such as COPD, 
kyphoscoliosis, and interstitial lung disease that may be responsible for the PH.  
COMPUTERISED TOMOGRAPHY OF THE CHEST  
 In most cases, a CT scan of the chest with high-resolution cuts should be 
performed to evaluate for the presence of parenchymal lung disease and mediastinal 
disorders that could cause obstruction of the pulmonary vessels. 
LUNG SCINTIGRAPHY  
 A ventilation-perfusion (V/Q) scan should be performed to evaluate for chronic 
thromboembolic disease. Prior studies have shown that V/Q scans have a high sensitivity 
and specificity for distinguishing between IPAH and chronic thromboembolic PH. 
Patients with a normal V/Q scan likely need no further evaluation for thromboembolic 
disease, but the poor correlation between the findings on V/Q scanning and the severity 
of vascular obstruction demands that those patients with a positive scan be sent for 
pulmonary angiography to accurately define the degree of vascular obstruction and to 
identify patients who would benefit from surgical thromboendarterectomy. 
 In addition to basic testing such as a complete blood count (CBC), an arterial 
blood gas (ABG), and a complete metabolic panel, the initial laboratory evaluation for 
patients with PH should include thyroid function tests, liver function tests (LFT), testing 
for collagen vascular diseases, and testing to detect the human immunodeficiency virus. 
PULMONARY FUNCTION TEST 
 All patients with PH should undergo baseline pulmonary function testing 
including spirometry, determination of lung volumes, and evaluation of the diffusion 
limitation for carbon monoxide (DLCO). Pulmonary function testing may reveal 
evidence of significant obstructive or restrictive ventilatory defects that may be relevant 
to the etiology of PH. 
SIX MINUTE WALK TEST  
 Quantification of exercise tolerance is often performed by measuring the distance 
that a patient can walk in 6 minutes (6MWD). The 6MWD is a useful tool for following 
patients over time and, for this reason, serial determinations of the 6MWD distance 
should be made. The 6MWD has been used to evaluate patients and has been utilized as a 
primary end point in recent clinical trials since earlier trials showed that 6MWD was 
predictive of survival in patients with IPAH. Arterial oxygen desaturation > 10% during 
6MWD has been shown to predict a 2.9 times increased risk of mortality over a median 
follow-up of 26 months. 
 
PULSOXIMETRY 
 Screening for unsuspected nocturnal hypoxemia and sleep apnea should also be 
performed in those patients newly diagnosed with PH. No further testing is warranted if 
overnight oximetry on room air shows no desaturation. Abnormal oximetry necessitates a 
full polysomnogram to formally diagnose and determine the severity of sleep apnea, as 
nocturnal hypoxia may be an aggravating or even a causative factor for PH.  
 Mechanisms of exercise limitation in PH include arterial hypoxemia, poor cardiac 
output and stroke volume in response to increased demand, lactic acidosis at low work 
rates, and V/Q mismatching. Cardiopulmonary exercise testing provides more 
physiologic information than the standard 6MWD; however, because it is technically 
more difficult, is time-consuming, is not available at all centers, and may be less sensitive 
at detecting responses to treatment, it is not routinely used. Patients with PAH typically 
show reduced peak VO2, reduced peak work rate, reduced anaerobic threshold, reduced 
peak oxygen pulse, increased VE and VCO2 slope indicating inefficient ventilation, and 
reduced ratio of VO2 increase to work rate increase. 
RIGHT HEART CATHETERISATION  
 Right heart Catheterisation (RHC) is initially performed for the purpose of 
diagnosing PH; other important information can also be obtained from this test. The right 
atrial pressure, the mixed venous oxygen saturation, the cardiac output and index, and the 
pulmonary vascular resistance all may be either measured or calculated during RHC. If a 
congenital heart defect or a left-to-right shunt is suspected, one may measure the oxygen 
saturation at several points throughout the course of the systemic venous system, right 
heart, and pulmonary arterial system looking for a step-up in saturation that would 
suggest the presence of a left-to-right shunt. Pressure measurements obtained during 
RHC have been used to derive a prediction equation that has been used to assess 
"predicted survival" and long-term effects of new treatments on survival.  
The equation to predict survival based on the National Institutes of Health (NIH) registry 
data is: 
P(t) = [H(t)]A(x,y,z); H(t) = [0.88 - 0.14t + 0.01t2]; A(x,y,z) = e(0.007325x + 0.0526y - .3275z) 
where P(t) = a patient's chances of survival at 't' years; t = 1, 2, or 3 years; x = mean 
pulmonary artery pressure; y = mean right atrial pressure; and z = cardiac index.[33] 
 If RHC confirms the diagnosis of PH, a vasodilator should be given to determine 
the degree of pulmonary arterial vasoreactivity, a factor that carries therapeutic and 
prognostic significance, as will be discussed later. No consensus exists regarding which 
agent should be used to perform this test; however, intravenous epoprostenol, intravenous 
adenosine, or inhaled nitric oxide is often chosen because all of these are potent yet short-
acting vasodilators. If the administration of a vasodilator causes the mean pulmonary 
arterial pressure to decrease ≥ 10 mmHg and reach ≤ 40 mmHg, with an unchanged or 
increased cardiac output, the patient is said to be vasoresponsive. The main reason for 
vasodilator testing is to identify patients who are likely to have a good long-term 
response to treatment with calcium channel blockers (CCBs) alone. Patients with IPAH 
are more likely to have a positive vasodilator response than those with PAH associated 
with collagen vascular diseases. Overall, only a minority of patients (approximately 10% 
to 15%) are likely to have a positive vasodilator response. 
MRI AND OPEN LUNG BIOPSY 
 The most recent recommendations from the ACCP did not advocate the routine 
use of magnetic resonance imaging (MRI) or open lung biopsy in the evaluation of 
patients with newly diagnosed PH. Cardiac MRI may provide additional pressure 
estimates and estimates of right ventricular mass and volume; however, at present the 
incremental value of this tool over standard testing measures is not sufficiently high to 
recommend its use in all patients.  
 Likewise, because of the risks associated with the procedure, The American 
College of Chest Physicians (ACCP) recommends lung biopsy “only if a specific 
question could be answered by tissue examination” in patients with PH and its “routine 
use to diagnose PH or determine its cause is discouraged.” Such indications could include 
the detection of pulmonary veno-occlusive disease, bronchiolitis, active vasculitis, or 
pulmonary capillary hemangiomatosis. 
BIOMARKERS 
 
 Candidate serum biomarkers that have been studied to evaluate and assess 
prognosis in IPAH include atrial naturetic peptide (ANP), brain naturetic peptide (BNP), 
catecholamines, and uric acid (UA). Nagaya and colleagues studied 63 consecutive 
patients with Idiopathic Pulmonary Hypertension (IPAH) between 1994 and 1999. 
Patients with IPAH underwent blood sampling at the time of baseline catheterization and 
subsequently treated with vasodilators. Patients were followed up for a mean follow-up 
period of 24 months. Plasma ANP and BNP levels were low in control subjects, and both 
were increased and correlated with functional class in patients with IPAH. ANP and BNP 
levels were also correlated with mean right atrial pressure (mRAP), mean pulmonary 
artery pressure (mPAP), cardiac output (CO) and total pulmonary resistance (TPR). 
Among the noninvasive parameters studied (NYHA-FC, echocardiographic parameters, 
and plasma levels of ANP, BNP, and catecholamines), only BNP was found to be an 
independent predictor of survival. Additionally, follow-up measurements were performed 
at 3 months after receiving prostacyclin therapy in 53 patients. Changes in plasma BNP 
levels correlated closely with changes in right ventricle end diastolic pressure (RVEDP) 
and TPR. Again, BNP level at 3 months was found to be an independent predictor of 
mortality. Furthermore, Kaplan-Meier survival curves demonstrated a marked increase in 
survival in those patients with a follow-up BNP level below the median value of 180 
pg/mL. Two studies assessed the relationship between plasma norepinephrine and 
mortality in patients with IPAH, and it was not found to be an independent predictor of 
mortality in either. Zaloga et al. showed that elevations in plasma NE are coincident with 
the presence of noncardiogenic pulmonary hypertension and that acute pharmacologic 
reduction of PVR does not normalize the loss of pulmonary NE metabolism. 
 Increased UA levels are believed to reflect impaired oxidative metabolism, since 
tissue hypoxia depletes adenosine triphosphate with degradation of adenosine nucleotides 
to compounds including UA. Since UA levels were shown to be associated with a poor 
prognosis in other disorders, investigators studied the association between serum UA 
levels and prognosis in patients with IPAH. Nagaya et al studied 102 consecutive patients 
over a long period of time. Follow-up was concluded in June 1998, for a mean duration of 
follow-up of 31 ± 37 months. Ninety-four percent of these patients were in NYHA-FC III 
or IV. Thirty age-matched, healthy volunteers served as control subjects. UA levels were 
significantly elevated in patients with IPAH as compared to control subjects for each 
gender group and the group as a whole. Serum UA levels increased in proportion to the 
severity of the functional class and correlated with CO, TPR, and MVO2. Among the 
noninvasive variables that were studied, serum UA levels were independently related to 
mortality.  
 Lopes and colleagues reported that plasma von Willebrand factor antigen 
(vWF:Ag) is elevated in patients with IPAH, PAH associated with CHD, and other 
assorted disorders. von Willebrand factor is a large multimeric glycoprotein that is 
synthesized and stored in endothelial cells. Therefore, it was hypothesized that levels of 
von Willebrand factor could be elevated in patients with PAH due to the associated 
abnormalities in endothelial cell function. Lopes and colleagues studied 11 patients with 
IPAH and 24 patients with PAH associated with CHD over a 1-year period. Twenty 
healthy volunteers served as the control group. Treatment included anticoagulation, 
antiplatelet agents, and "anticongestive" measures. vWF:Ag was elevated in patients with 
PAH as compared to control subjects, and more so in patients with IPAH than with CHD. 
Multivariate analysis showed that cause of PH and vWF:Ag levels were independently 
associated with survival.  
 
ROLE OF ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION  
 Pulmonary hypertension is easily recognized when the following M Mode and 
two dimensional echocardiographic features are present. 
- Diminished or absent ‘a’ (atrial) wave of the pulmonary wave. 
- Midsystolic closure or the notching of the pulmonary valve. 
- Enlarged chambers on the right side of the heart. 
- D-shaped left ventricular cavity caused by a flattened ventricular septum. 
 However, these features are not sensitive for pulmonary hypertension and are not 
predictive of right ventricle dysfunction. In a sense, these features are only qualitative 
and do not provide actual hemodynamic data. 
 Doppler echocardiography allows estimation of pulmonary artery pressures and 
PVR by measuring tricuspid regurgitation velocity, pulmonary regurgitation velocity and 
right ventricle outflow tract (RVOT) flow velocity.  
 The American College of Chest Physicians (ACCP) Clinical Practice Guidelines 
emphasize the use of echocardiography in pulmonary arterial hypertension (PAH) with 
much of the discussion involving the estimate of right ventricular systolic 
pressure(RVSP). As indicated in the The American College of Chest Physicians (ACCP) 
consensus guidelines, Doppler echocardiography is the “test of choice” for noninvasive 
measurement of pulmonary arterial pressure in patients in whom PAH is clinically 
suspected. 
 Less widely recognized—and probably underemphasized in the clinical practice 
guidelines—is the value of echocardiography in assessing end-organ manifestations of 
severe PAH. Right ventricular failure is the most common cause of death in patients with 
PAH, and the results of several observational studies suggest that echocardiographic 
evaluation of right ventricular structure and function can provide important prognostic 
information.  A Doppler-derived index of right ventricular myocardial performance 
(MPI) that represents the sum of isovolumetric contraction and relaxation times divided 
by the ejection time. This index of global right ventricular function was a potent and 
independent predictor of cardiac death and lung transplantation. 
 Two studies have evaluated Doppler echocardiographic-derived indices of RV 
function in patients with IPAH. The Doppler echocardiographic index, at times referred 
to as the Tei index, is calculated as follows: the sum of the RV isovolumetric contraction 
time and the isovolumetric relaxation time are obtained by subtracting RV ejection time 
from the interval between cessation and onset of the tricuspid velocities with pulsed-wave 
Doppler echocardiography. The index of combined RV systolic and diastolic function is 
obtained by dividing the sum of both isovolumetric intervals by ejection time. In a small 
study of 26 consecutive patients with IPAH, all six patients who died during the follow-
up period had a Doppler echocardiography RV index above the median. A larger series of 
53 patients with IPAH followed up over a mean of 2.9 years from the same institution 
confirmed the predictive value of the Doppler echocardiography RV index. On univariate 
analysis, an elevated Doppler echocardiography RV index (p < 0.0001) was the strongest 
predictor of an adverse outcome, which was defined as death or lung transplantation. 
Other echocardiographically derived univariate predictors included severity of TR (p = 
0.004) and heart rate (p = 0.02). Multivariate regression analysis also identified the 
Doppler echocardiography RV index as prognostic of adverse outcome (p = 0.004). 
 Abnormalities in the Doppler flow velocity patterns of right ventricular ejection 
(due to increased right ventricular impedance) and left ventricular filling (due to 
abnormal ventricular interaction) are common findings in patients with severe PAH. In 
patients with PH, a short right ventricular acceleration time (<62 ms) and a ratio of early 
to late transmitral flow velocities (E/A) <1 were associated with reduced survival.  
 Structural manifestations of right ventricular decompensation— right atrial 
enlargement (RAE) and paradoxical displacement of the interventricular septum (IVS) 
were indicative of a poor prognosis in patients with PAH and WHO Class III or Class IV 
symptoms. A planimetered right atrial area in the apical four-chamber view exceeding 20 
cm2/m and a value >2 for the end-diastolic eccentricity index—a simple measure of 
septal displacement measured from the parasternal short axis view—were also associated 
with a poor prognosis. The presence of a pericardial effusion, a common finding in 
patients with severe PAH that reflects an elevated right atrial pressure, was a powerful 
and independent predictor of mortality in PAH. In a series of 26 patients with Idiopathic 
PAH receiving conventional therapy, Eysmann and colleagues studied 41 
echocardiographic variables and 9 cardiac catheterization variables. Although several 
factors were prognostic on univariate analysis, multivariate life-table analysis of 
noninvasive variables revealed the severity of pericardial effusion to be independently 
significant (p = 0.006). In an analysis of 79 of 81 Idiopathic PAH patients who 
participated in the randomized trial of IV epoprostenol, pericardial effusion was noted in 
43 patients (54%). Patients with larger effusions generally had more severely impaired 
exercise performance. Larger effusion size was also correlated with more RA dilatation, 
greater displacement of the intraventricular septum during diastole, and more TR than 
patients with no or trace effusion. Although there was not an association between 
pericardial effusion and mortality at the end of the 12-week study, effusion size was 
correlated with death (p = 0.02). 
 Therefore, there is ample evidence to support a comprehensive echocardiographic 
examination to assess the extent of target organ disease as an important component of the 
routine evaluation. The assessment by an experienced echocardiographer of the degree of 
right ventricular enlargement and dysfunction, utilizing simple measures—the presence 
of a pericardial effusion, an E/A ratio <1, a right ventricular acceleration time <62 ms, a 
planimetered right atrial size >20 cm2/m, and a diastolic eccentricity index >2—or more 
complex parameters, such as the Doppler right ventricular index or the Tei Index, can 
complement the clinical evaluation in assessing prognosis and guiding therapy. 
 PROGNOSIS IN PULMONARY HYPERTENSION AS RECOMMENDED BY 
ACCP 
.  In patients with Pulmonary hypertension, the following parameters, as assessed at 
baseline, may be used to predict a worse prognosis, as suggested by The American 
College of Chest Physicians.  
 
1. Advanced NYHA-FC. Quality of evidence: good; net benefit: substantial; 
strength of recommendation: A.  
2. Low 6MWT distance. Quality of evidence: good; net benefit: substantial; 
strength of recommendation: A.  
3. Presence of a pericardial effusion. Quality of evidence: good; net benefit: 
substantial; strength of recommendation: A.  
4. Elevated mRAP. Quality of evidence: fair; net benefit: substantial; strength of 
recommendation: A.  
5. Reduced CI. Quality of evidence: fair; net benefit: substantial; strength of 
recommendation: A.  
6. Elevated mPAP. Quality of evidence: fair; net benefit: intermediate; strength of 
recommendation: B.  
7. Elevated Doppler Echocardiography RV (Tei) index. Quality of evidence: low; 
net benefit: intermediate; strength of recommendation: C.  
8. Low VO2max and low peak exercise SBP and DBP as determined by CPET. 
Quality of evidence: low; net benefit: intermediate; strength of recommendation: 
C.  
9. ECG findings of increased P-wave amplitude in lead II, qR pattern in lead 
V1, and World Health Organization criteria for RV hypertrophy. Quality of 
evidence: low; net benefit: intermediate; strength of recommendation: C.  
10. Elevated BNP (> 180 pg/mL). Quality of evidence: low; net benefit: 
intermediate; strength of recommendation: C.  
11. In patients with IPAH treated with epoprostenol, persistence of NYHA-FC III 
or IV status after at least 3 months of therapy may be used to predict a worse 
prognosis. Quality of evidence: fair; net benefit: substantial; strength of 
recommendation: A.  
12. In patients with scleroderma-associated PAH, reduced DLCO (< 45% of 
predicted) may be used to predict a worse prognosis. Quality of evidence: low; 
net benefit: small/weak; strength of recommendation: C.  
13. In pediatric patients with IPAH, younger age at diagnosis may be used to 
predict a worse prognosis. Quality of evidence: low; net benefit: small/weak; 
strength of recommendation: C.  
ECHOCARDIOGRAPHIC VIEWS OF THE RIGHT HEART 
 Owing to the complexities in the geometry of the right heart, no single view is 
sufficient to visualize the right heart. The RV inflow is best seen with anterior and medial 
angulation of the transducer in the standard parasternal long axis view. The parasternal 
short axis view is useful for visualizing the base of the right heart, RA and IAS, RV 
outflow tract, pulmonary valve and MPA and its branches. Forward and regurgitant flow 
in pulmonary valve is seen in this view. Geometry and motion of the right ventricle is 
seen from the apical four chamber view. Doppler interrogation of tricuspid regurgitation 
is optimal in this view. 
 
ECHOCARDIOGRAPHIC INDICES FOR RIGHT VENTRICLE DYSFUNCTION 
– A PERSPECTIVE 
MYOCARDIAL PERFORMANCE INDEX – TEI INDEX. 
 Studies have found several novel echocardiographic and Doppler measurements 
of RV function to be risk factors for heart failure, independently of traditional risk factors. 
For example, Myocardial Performance Index (MPI) provided prognostic information 
beyond that of other measurements of cardiac function and traditional risk factors.  
 MPI has previously been shown to have prognostic value in patients with dilated 
cardiomyopathy, amyloidosis, coronary heart disease and symptomatic heart failure as 
well as in the general population. MPI provides prognostic information independently of 
other measurements of cardiac function and of traditional risk factors for heart failure. 
Therefore, MPI seem to be a clinically relevant measurement of global ventricular 
function and may prove to be a valuable tool in assessing the risk of developing right 
heart failure.  
 Our knowledge of the natural history of heart failure indicates that both 
asymptomatic systolic and diastolic dysfunction can precede the onset of overt heart 
failure. The utility of Myocardial Performance Index (MPI) is comparable to 
simultaneous cardiac catheterization measurements of right ventricular function as the 
MPI was found to reflect both systolic and diastolic function. 
 MPI mirrors both the depolarization and repolarization process. It seems like 
changes in cellular Ca2+ handling in the myocardium underlie much of the abnormal 
contractility and relaxation. In the failing heart, the contraction and relaxation becomes 
slower explaining why MPI increases with deterioration of cardiac function. There is 
evidence that sub-clinical depolarization (and repolarization) defects to be early 
phenomena in the natural history of heart failure as noted above. 
 Myocardial performance Index is a unit less number reflecting the global 
performance of the ventricle. It was devised in the mid 1990’s (Tei et al). It is a simple 
index which incorporates both systolic and diastolic parameters and can be applied to 
either left or right ventricle. Several studies have used this index as a prognostic indicator 
of left ventricular performance. The utility of MPI as an indicator of global RV 
performance is an area of interest in the recent past. 
 The ratio of isovolumic contraction time(IVCT) and ejection time (ET) was 
closely correlated to +dP/dt (reflecting systolic function) and the ratio of isovolumic 
relaxation time(IVRT) and ejection time was closely correlated to –dP/dt and s (reflecting 
diastolic function). Therefore, MPI may be considered the sum of an index reflecting 
systolic function and an index reflecting diastolic function. Thus, the superior predictive 
capacity of MPI could be explained by the fact that MPI reflects global  function, while 
other measurements are limited to reflect mainly either LV systolic or diastolic function.  
     IVRT + IVCT 
   M P I  = 
             ET  
 According to the above equation, systolic dysfunction is characterized by the 
prolongation of IVCT and decrease in ET. Whereas the diastolic dysfunction is 
characterized by the lengthening of IVRT. Presence of both is indicated by an increase in 
MPI. The normal value of MPI of Left ventricle is 0.39 +/- 0.08. 
 MPI is helpful in risk stratification of patients with pulmonary hypertension. For 
the right heart, the normal values are 0.28 +/- 0.04. An increase in the right ventricle MPI 
is a very sensitive and specific marker of pulmonary hypertension. Thus MPI is of value 
in patients in whom tricuspid regurgitation is either not present or cannot be quantified to 
assess the severity of pulmonary hypertension. 
 Thus, MPI is a reliable and easily assessable measurement of global ventricular 
function, and as such, suitable for large-scale examinations. Nevertheless, further studies 
are needed in order to define the role of MPI in clinical practice. Clinically significant 
age- and gender-specific cut-off points need to be defined; furthermore it has to be 
determined if pharmacological and/or non-pharmacological interventions lower MPI and 
whether lowering MPI modifies the risk associated with a high MPI. 
ISOVOLUMETRIC CONTRACTION TIME (IVCT) & ISOVOLUMETRIC 
RELAXATION TIME (IVRT) 
 Isovolumetric phase is the earliest phase of ventricular systole in which the 
ventricle contracts as a closed chamber without any change in the volume of the chamber. 
The isovolumic contraction time corresponds to when calcium enters the myoplasm from 
the sarcolemma. 
 Traditionally IVRT is recorded as the aortic valve closure and mitral valve 
opening time in the Left ventricle. M Mode echocardiography and pulsed wave Doppler 
were used for this purpose. Normal values approximates 65 +/- 20 msec. Isovolumic 
relaxation time reflects the removal of Ca2+ from the myoplasm by Ca2+-ATPases.  
 Recently continuous wave Doppler echocardiography has been used to measure 
IVRT. The Apical 5 chamber view is used for this purpose. Measurements made by this 
method is comparable to that made by invasive methods. IVRT represents the earliest 
phase of ventricular diastole. Abnormalities of this index has been described as a non 
invasive predictor of diastolic dysfunction. However, measurement of IVRT as the sole 
indicator of diastolic dysfunction is limited, since no information on ventricle filling is 
provided.  
RIGHT VENTRICLE SYSTOLIC FUNCTION 
 Right ventricle systolic function can be evaluated in several ways. It is affected in 
several situations like Inferior myocardial infarction, pulmonary hypertension and 
arrhythmogenic right ventricular dysplasia. As with left ventricle, wall motion 
abnormality can be assessed in RV. Both right ventricle free wall and IVS should be 
evaluated. It provides a qualitative assessment of RV systolic function. A more 
quantitative approach involves the measurement of right ventricle volume and area at end 
diastole and end systole. RV area fractional shortening and Ejection fraction can be 
calculated. This can be measured using the M mode echocardiography from the apical 4 
chamber view. 
 
RIGHT ATRIAL AND RIGHT VENTRICLE DIMENSIONS IN 
ECHOCARDIOGRAPHY 
 For several reasons, the right heart anatomy and function is a complex one and 
has not been well studied. The right atrium is abnormal in both right ventricle volume and 
pressure overload states and RV failure. It is best visualised in echocardiography by the 
apical 4 chamber view or the sub costal view. RA dimensions can be measured in 2 ways. 
The Linear dimensions in 2 different axes and planimetry method are currently used. 
Another qualitative method of assessing RA size is to compare it with the Left atrium 
size. If the RA size is greater than the LA size, then RA enlargement is inferred. 
 Right ventricle dimension assessment is very difficult for the following reasons. 
Firstly, the complex anatomical shape – cresentic shape of the cavity. Secondly, the 
presence of irregular endocardial surface. Thirdly, the complexity in its contraction 
mechanics, comparable to that of bellows. Lastly its location immediately behind the 
sternum also poses a problem in the evaluation of RV anatomy and function. 
 RV is cresentic in its minor axis, but along its long axis it is complex. There is no 
simple geometric three dimensional figure accurately represents this chamber. 
Contraction is also complex as mentioned above. Relatively small movements produce 
large ejection volumes. Normally the RV is two thirds of the size of Left ventricle. To 
measure the RV dimensions and volumes, both the area – length and Simpson s rule has 
been employed. The area – length method measures: the estimate of short axis and a 
linear measure of length from the apical 4 chamber view. Recently three dimensional 
echocardiography has resolved the problem in the techniques that assumptions about the 
shape to be made and also there was a lack of gold standard for comparison. 
RIGHT VENTRICULAR ABNORMALITES IN PULMONARY HYPERTENSION 
 The role of RV is to deliver oxygen deficient blood to the gas exchange 
membranes of the pulmonary circulation. Under normal circumstances, there is little 
impedance with the resistance only about 1/10th of that in the systemic circulation. 
Consequently a very low pressure gradient of only 5mmHg is required to pump blood 
into the pulmonary circulation. In addition the pressure overload on the right ventricle is 
prevented by the recruitment of newer vessels and distension of the compliant vessels in 
the pulmonary circulation. 
 Right ventricular performance is influenced by contractile state of the 
myocardium and extrinsic factors, including loading conditions, LV performance, 
pericardial constraint, coronary perfusion, function of the IVS and intrapericardial 
pressure. In the setting of pulmonary diseases, it is the alteration of loading conditions 
that is the greatest influence on the heart 
 Pathophysiologic response of the right ventricle or dysfunction of the right heart 
can be due to pressure overload, volume overload and ischemia. Distinguishing between 
them is a key factor in ascertaining the etiology of the RV failure. The hemodynamic 
response to pulmonary vascular diseases causing pulmonary hypertension is a pressure 
overload state. 
 Pressure overload of RV results in hypertrophy of both the RV free wall and the 
IVS. This is often associated with increase in the trabeculations of the right ventricle. The 
parasternal long axis view is used for the measurement of RV free wall thickness. RV 
pressure overload also results in the flattening of the interventricular septum. It is the 
result of abnormal pressure gradient between the left and right ventricle. A characteristic 
feature of the RV pressure overload is the presence of the flattening of IVS through out 
the cardiac cycle in contrast from the RV volume overload where the flattening is a 
feature only in diastole. 
 Weimann et al demonstrated the mechanism of paradoxical septal motion in 
patients with right ventricular volume overload (RVVO). Short axis cross-sectional, 
echocardiographic studies of the left ventricle (LV) and interventricular septum (IVS) 
were performed in  patients with paradoxical septal motion due to RVVO and in normal 
subjects. Short axis study in normal subjects revealed the left ventricle to be a relatively 
circular structure during both diastole and systole. In patients with RVVO a change in LC 
diastolic shape was observed. This change in shape varied from a slight flattening of the 
LV and IVS during diastole to total reversal of the normal direction of septal curvature 
such that the IVS became concave toward the RV and convex toward the LV. During 
systole the LV and IVS returned to their normal relatively circular configuration. This 
change in LV shape from diastole to systole resulted in net motion of the IVS toward the 
right ventricle (paradoxically). This study therefore suggests that paradoxical septal 
motion in patients with right ventricular volume overload is a result of a change in the 
diastolic shape of the left ventricle. In patients with RV pressure overload, the IVS 
paradoxical motion persisted through out the cardiac cycle. 
 Doppler imaging is also very useful in RV pressure overload. Pulmonary valve 
flow and tricuspid regurgitation velocity can be measured. The acceleration time is the 
time from onset to peak velocity which provides a rough estimate of increase in 
pulmonary artery pressure. The shorter the acceleration time, greater is the pulmonary 
artery pressure. Tricuspid regurgitation develops early in RV dysfunction, although 
severe regurgitation develops only in severe RV failure. 
 In patients with severe pulmonary hypertension, RV is dilated when viewed from 
the apical 4 chamber view. A subjective criterion for RV dilatation is a right ventricular 
diastolic area equal to or greater than that of the left ventricle. RV dilatation is also 
observed in conditions producing right ventricle volume overload conditions. Such 
conditions can be differentiated from those produced by RV pressure overload by a high 
eccentricity index that persists only in diastole and normalizes in systole. Eccentricity 
index is derived from the ratio of two orthogonal minor axis measured from the short axis 
view. The normal value is 1.0. In conditions producing septal flattening, index is greater 
than 1.0.     
PULMONARY ARTERY SYSTOLIC AND DIASTOLIC PRESSURES  
 A more direct measure of the RVSP is done by measuring the tricuspid 
regurgitation jet velocity. Bernoulli s equation is used to calculate the pressure gradient 
between RV and RA.  
Then RVSP is calculated by 
  RVSP = 4 (TR velocity) 2 + P RA 
Where TR velocity is the maximum velocity of the TR jet in m/sec and P RA is the pressure 
in RA. 
 With pulmonary hypertension, pulmonary artery diastolic pressure increases 
disproportionately creating a high pressure gradient and hence an increased end-diastolic 
regurgitant velocity. Thus in pulmonary hypertension, pulmonary regurgitant velocity at 
end diastole is >2 m/sec. 
LIMITATIONS OF DOPPLER ECHOCARDIOGRAPHY 
 Studies have demonstrated that the concordance between Doppler 
echocardiography and direct measurement via RHC worsens as the pressure rises, with 
poorest correlation when the systolic pulmonary pressure is over 100 mmHg. Doppler 
echo may also overestimate systolic PAP in a population comprising people with normal 
pressure. 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
- To study the clinical profile of Idiopathic Pulmonary Hypertension patients. 
- To study the utility of echocardiography in assessing the right ventricular function 
in patients with idiopathic pulmonary hypertension. 
- To measure the Pulmonary artery systolic pressure in Idiopathic Pulmonary 
hypertension using  Doppler Echocardiography. 
- To assess the structural abnormalities of the heart in patients with idiopathic 
pulmonary hypertension.  
- To study the correlation between the clinical grading of severity and 
echocardiographic grading of pulmonary hypertension. 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 About 25 patients who got admitted to the Department of Medicine and 
Cardiology in Govt Rajaji Hospital, Madurai between July 2006 and July 2007 were 
chosen and studied.  
The type of study : analytical study 
Selection criteria  and study population : 
Inclusion criteria  
 Twenty five patients (mean age 27.64±8.18 years, 22 females) who were admitted 
to our hospital and found have to have Pulmonary Hypertension of obscure/unknown 
etiology underwent a complete clinical and echocardiographic examination. In the 
population studied, pulmonary hypertension of varying severities were detected, as 
determined by Doppler echocardiography. 
Exclusion criteria  
 Pediatric age group patients were not included in the study. Patients with Chronic 
Obstructive pulmonary Disease, cardiomyopathy, abnormal left ventricular systolic 
function, valvular heart disease or congenital heart disease with Left to right shunt lesions 
were all excluded. 
 The Institutional ethical committee approved the study and all patients gave 
informed consent to undergo evaluation. 
 
Methods : 
 All the patients included in the study were subjected to detailed history taking and 
complete physical examination. They were also evaluated for the etiology for pulmonary 
hypertension with complete blood count (CBC), Renal function testing (RFT), Liver 
function testing (LFT), Thyroid function testing (TFT), HIV ELISA, Anti nuclear 
antibodies (ANA), Chest X Ray, USG abdomen, High resolution Computed Tomography 
of the Chest (HRCT) ,Pulmonary function testing (PFT).  
 Clinical grading of pulmonary hypertension severity was done according to the  
WHO functional classification. 
Class I: Patients with PH without limitation of usual activity  
Class II: Patients with PH with slight limitation of usual physical activity  
Class III: Patients with PH with marked limitation of usual physical activity  
Class IV: Patients with PH with inability to perform any physical activity without 
symptoms and who may have signs of right ventricular failure. 
 All patients underwent a complete transthoracic echocardiographic study 
including two-dimensional, M Mode, color flow and spectral Doppler using ALOKA 
SSD 4000 echocardiography machine. Continuous ECG monitoring of the patients was 
done during the procedure with the patient lying in standard left lateral decubitus 
procedure.  
 Standard two-dimensional echocardiographic evaluation of right atrium (RA) and 
right ventricle (RV) size and function was performed. The right atrium and right ventricle 
were visualized by the apical four chamber view (fig 8). RA size was evaluated using 
linear dimensions in the minor axis. Modified Simpson’s rule was employed for 
estimating RV area (fig 9). In addition, right ventricular end-diastolic (RV EDA) and 
end-systolic areas (RV ESA) were measured from the apical 4-chamber view to calculate 
right ventricular fractional area change (RV FAC). The main pulmonary artery (MPA) 
and ascending aorta were optimally visualized using the parasternal long axis views. The 
pulmonary artery size was measures below the pulmonic valve (fig 10). M mode and two 
Dimensional echocardiography were used to document presence or absence of pericardial 
effusion. The free fluid in the pericardial cavity was visualized as an echo-free space 
using the parasternal long axis and short axis views. Isovolumetric contraction time 
(IVCT), isovolumetric relaxation time (IVRT) and ejection time (ET) were measured 
across the tricuspid valve using the pulsed wave Doppler echocardiography during the 
tricuspid valve flow and subsequently right ventricular Myocardial Performance Index 
(MPI) or the Tei index was calculated using the standard formula  MPI  = IVRT+IVCT / 
ET. 
 .Paradoxical septal motion was visualized in the parasternal long axis view and  
the ‘D’ sign was visualized by the parasternal short axis view as a flattening of the 
septum (fig 12). Pulmonary artery systolic pressures (PASP) were estimated using the 
approach of calculating the systolic pressure gradient between right ventricle and right 
atrium by the maximum velocity of the tricuspid regurgitant jet in continuous wave 
Doppler study using the modified Bernoulli equation and then adding to this value an 
estimated right atrial pressures based on both the size of the inferior vena cava and the 
change in caliber of this vessel with respiration (fig 13 & 14). M mode echocardiography 
was used to study the ‘a’ wave of the pulmonary valve and midsystolic notching or 
closure of the valve (fig 11). Contrast study with agitated normal saline was done to rule 
out congenital or acquired shunt lesions. All the patients in our study had normal left 
ventricular systolic function and normal valves. 
 The reference limits for various echocardiographic indices and parameters used in 
this study were adopted from the standard echocardiographic manuals. The diagnosis of 
pulmonary hypertension and severity grading was done as follows : 
Pulmonary Artery Systolic Pressure (PASP) measured  > 25 mmHg at rest was 
considered to be pulmonary hypertension. 
variable MILD MODERATE SEVERE 
PASP mmHg 25-50  51-75  >75 
 
 The reference limits for the main pulmonary artery (MPA) diameter measured 
below the pulmonary valve: 
variable Reference range Mildly  
Dilated 
Moderately 
dilated 
Severely 
dilated 
Pulmonary 
artery size, cm 
1.5 – 2.1 2.2- 2.5 2.6-2.9 ≥ 3.0 
 
 The reference limits for Right atrial (RA) minor axis dimension measured in 
apical four chamber view are: 
variable Reference 
range 
Mildly 
enlarged 
Moderately 
enlarged 
Severely 
enlarged 
RA minor axis 
dimension, cm 
2.9 – 4.5 4.6 – 4.9 5.0 – 5.4 ≥ 5.5 
 
 The reference limits used for the myocardial performance index for the right 
ventricle is 0.28 ± 0.04.  
 The reference limits used for right ventricle end systolic area (RV ESA), right 
ventricle end diastolic area (RV EDA) and right ventricle fractional area change (RV 
FAC) are as follows: 
Variable Reference 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
RV diastolic 
area, cm2 
11 – 28 29 – 32 33 – 37 ≥38 
RV systolic 
area, cm2 
7.5 – 16 17 – 19 20 – 22  ≥23 
RV fractional 
area change % 
32 – 60 25 – 31 18 – 24  ≥17 
 
 M mode and 2 D echocardiography measurements of the echo-free space were 
used to grade the severity of pericardial effusion. 
variable Mild Moderate large 
Echo free space, 
cm 
<1 1 – 2 >2 
 
Statistical Tools  
 The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2002).Using this software, frequencies, percentage, mean, 
standard deviation, x2 and 'p' values were calculated. A 'p' value less than 0.05 is taken 
to denote significant relationship. 
 
 
 
 
  
RESULTS 
 The results of clinical evaluation of the 25 patients are shown below. The table 1 
and Fig 1 show the age wise distribution of IPAH in our study. The mean of age of 
patients in our study is 27.64 ± 8.18 years. 
Table 1 
Age wise distribution of the disease 
 
Cases Age (In Years) 
No. % 
Less than 20 3 12 
20-24 9 36 
25-29 3 12 
30-34 4 16 
35-39 3 12 
40 & above 3 12 
Total 25 100 
Mean 
S.D. 
27.64 yrs 
8.18 yrs 
 
 
  
 
 
 
 
 The number of patients belonging to each WHO functional class is shown in 
Table 2 and Fig 2. 
. Table 2 
WHO Functional Classification 
 
Cases WHO Class 
No. % 
I - - 
II 6 24 
III 11 44 
IV 8 32 
Total 25 100 
 
 
 The table 3 below shows there is no statistical correlation between WHO 
functional class severity and age of the patients.  
 
Table 3 
Relationship between WHO functional classification and Age 
 
Age in years WHO Classification 
Mean S.D. 
II 24.5 7.12 
III 30 9.27 
IV 26.75 7.23 
‘P’ 0.4748 (Not significant) 
 
 The table 4 and Fig 3 show the sex wise distribution of the disease. Of the 25 
patients, 22 (88%) were females and 3 (12%) were males. 
Table 4 
Sex Distribution 
 
Cases Sex 
No. % 
Male 3 12 
Female 22 88 
Total 25 100 
 
 All the patients in WHO functional class II (n=6) were females. About 91% of the 
patients in class III (n=11) were females and 9% were males. Class IV (n=8) had 75% 
females and 25% males. The table 5 shown below illustrates the findings. 
Table 5 
WHO Classification and Sex 
 
Males Females 
WHO Classification 
No. % No. % 
II (6) - - 6 100 
III(11) 1 9.1 10 90.9 
IV (8) 2 25 6 75 
  
 
  
 
 
 
 
AGE DISTRIBUTION 
FIG 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12%
36%
16%
12%
12%
12%
Less than 20 20-24 25-29 30-34 35-39 40&above
  
 
WHO FUNCTIONAL CLASSIFICATION 
FIG 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24%
44%
32%
0%
II III IV Slice 4
  
 
 
 
SEX DISTRIBUTION 
 
FIG 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12%
88%
0%
0%
MALES FEMALES
 The table 6 shows the common symptoms in our study population. Dyspnea on 
exertion is the most common symptom and was found in all our patients (100%). Fatigue 
is the second most common symptom in our patients (68%). 
Table 6 
Symptoms 
Symptoms No. % 
Dyspnea on exertion 25 100 
Chest Pain 10 40 
Giddiness 11 44 
Syncope 2 8 
Cough / Sputum 15 60 
Palpitations 13 52 
Pedal edema 13 52 
Hemoptysis 5 20 
Fatigue 17 68 
  
 The correlation between the number of symptoms at the time of presentation and 
WHO functional class severity was statistically significant ( p = 0.0228). 
Table 7 
WHO Classification and number of symptoms present 
Number of symptoms present 
WHO Classification 
Mean S.D. 
II 5.0 1.41 
III 3.82 1.25 
IV 5.63 1.06 
‘p’ 0.0228 ( Significant) 
 
 Among the 25 patients, 23 patients (92%) showed some abnormality in the 
complete blood count (CBC) and anemia was the most common abnormality and CBC 
was normal in the rest. 24 patients (96%) showed ECG abnormalities in the form of sinus 
tachycardia, right atrial enlargement and right ventricular hypertrophy and right axis 
deviation (fig 4). 23 patients (92%) showed chest X ray evidence of pulmonary artery 
dilatation (fig 5). 1 patient (4%) showed evidence of apical fibrosis of right lung and 1 
patient (4%) had a normal CXR. 
 The renal function testing, liver function testing and thyroid function testing 
revealed no abnormalities in the study population. HIV ELISA and anti nuclear 
antibodies were negative in all the patients included in our study. High resolution 
computed tomography of the chest showed no abnormalities of the pulmonary 
parenchyma and ruled out the possibility of pulmonary thromboembolic disease in our 
patients (fig 6).  
 The table 8 shows the echocardiograpic parameters measured to assess right heart 
structural changes and functional abnormalities. The mean size of the right atrium was 
4.69 ± 1.22 cm. The right ventricle dimension as determined using simpsons rule had a 
mean value of 28.93 ± 8.45 cm2 (fig 9). The mean PASP in our patients was 92.52 ± 
35.29 mm Hg. 5 patients (25%) had mild pulmonary hypertension, 2 patients (10%) had 
moderate pulmonary hypertension and 18 patients (65%) had severe pulmonary 
hypertension. The mean fractional area change in right ventricle is 18.48 ± 5.71 %. The 
mean value of MPI was 0.821 ± 0.205. 
 
 
Table 8 
Echocardiographic measurements in our patients 
Parameter Mean S.D. 
RA cm 4.69 1.22 
RV cm2 28.93 8.45 
MPA cm 2.64 0.67 
TRPG 82.52 35.29 
PASP 92.52 35.29 
RVESA 22.36 3.35 
RVEDA 35.84 3.59 
RVFAC 18.48 5.71 
IVCT 82.08 14.14 
IVRT 123.04 27.53 
ET 256.7 41.2 
MPI 0.821 0.205 
 
  Echocardiography showed that 14 patients (56%) had pericardial effusion, 
20 patients (80%) had paradoxical motion or flattening of the interventricular septum. All 
the patients included in the study showed features of absent ‘a’ wave and presence of mid 
systolic notch in the pulmonary valve. Bubble study was negative in all the patients 
ruling out the possibility of abnormal left to right shunts. All patients had normal left 
ventricular systolic function. 
 The table 9 and Fig 7 show that the relationship between the RA size, RV size, 
Pulmonary artery size and the WHO functional class. Likewise the Table 10 shows 
statistically significant relationship between WHO functional class and 
echocardiographic indices for RV dysfunction like RV FAC and  MPI. 
 
Table 9 
Relationship between WHO Functional Classification and structural abnormalities 
 
WHO Classification 
II III IV Parameter 
Mean S.D. Mean S.D. Mean S.D. 
‘p’ 
RA cm 2.98 0.48 5.03 0.86 5.5 0.69 0.0008 (Significant) 
RV cm2 15.05 2.79 32.34 3.29 34.67 1.54 0.0006 (Significant) 
MPA cm 1.9 0.32 2.96 0.62 2.74 0.52 0.0041(Significant) 
 
Table 10 
Relationship between WHO Classification and Echocardiographic Indices 
 
WHO Classification 
II III IV Parameter 
Mean S.D. Mean S.D. Mean S.D. 
‘p’ 
TRPG 39.17 7.52 81.72 21.8 116.13 25.46 0.0002(Significant) 
PASP 49.17 7.52 91.73 21.8 126.13 25.46 0.0002(Significant) 
RVESA 17.5 1.52 23.45 2.38 24.5 1.2 0.0012(Significant) 
RVEDA 31.67 2.07 37.09 3.45 37.25 2.12 0.0059(Significant) 
RVFAC 26.67 2.34 16.18 2.6 15.5 4.72 0.0016(Significant) 
MPI 0.641 0.084 0.783 0.160 1.049 0.085 0.0001( Significant) 
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DISCUSSION 
 Demographic studies with respect to IPAH are very limited in India. According to 
one report, there are 2 cases per million population in the west. Exact incidence and 
prevalence rates could not be calculated from our study. There is a strong female 
preponderance in patients with IPAH. The male : female ratio in our study is 
approximately 1:8. The most common age group affected in our study population was in 
the 3rd and 4th decade in contrast to the reports from the west which have reported higher 
incidence of IPAH in 4th or the 5th decade. The reason for the early presentation in our 
study population is not known. The role of genes in determining the onset of disease and 
disease severity is still unsettled.  
 Most patients in our study shared the clinical presentation. Exercise intolerance in 
the exertional dyspnea and fatiguability were most common clinical manifestations in our 
study populations. 100 % of our patients had dyspnea as opposed to 60 % reported in 
another study. Other common symptoms include chest pain (40%), cough (60%) 
giddiness (44%) and pedal edema (52%). The number of symptoms at the time of 
presentation had an effect on the severity of the disease. Patients with more clinical 
symptoms belonged to higher WHO functional class and had higher values of  PASP. 
 Echocardiography developed over the last three decades has become an extension 
of the physical examination in the modern evaluation of a patient with heart disease. The 
review of the various studies shows this unique non invasive technique is useful in 
knowing the anatomical and pathophysiological alterations and in the hemodynamic 
evaluation of any case of disease leading to heart failure.  
 The results of this study suggest that right ventricular dysfunction , represented by 
both structural and pathophysiological abnormalities occurs in patients with pulmonary 
hypertension. Right ventricular abnormalities occurred even with mild elevations of 
pulmonary artery pressure. In addition, they correlate well with markers of disease 
severity including pulmonary hypertension severity index, World Health Organization 
functional class. (p < 0.05) 
 Among the structural abnormalities, the right ventricle dimension had a higher 
statistically significant correlation of WHO functional class severity (p = 0.0006) when 
compared to RA size (p = 0.0008) and MPA size (p = 0.0041). 
 The results of this study can be quite useful in the evaluation of chronic 
pulmonary hypertension patients given the well-know limitations of standard 
echocardiography in the assessment of right ventricular size and function due to the 
complex structure and asymmetrical shape of this cardiac chamber. The changes in right 
ventricular area obtained from the apical 4-chamber views were taken as indices of right 
ventricular size and global systolic function rather than ventricular volumes and ejection 
fraction, which appeared to be influenced by many factors. In addition RV Myocardial 
Performance Index, a well-recognized measure of global ventricular systolic and diastolic 
function that is independent on any geometric assumptions and heart rate was calculated 
from IVCT, IVRT and ET.  
 In our study, Myocardial Performance Index was found to have the highest 
correlation to WHO functional class severity (p = 0.0001). RV FAC (p = 0.0016) and 
PASP (p = 0.0002) also showed statistically significant correlation to WHO class. Thus 
MPI is the most sensitive and specific marker of RV dysfunction in patients with 
pulmonary hypertension. 
 The value of MPI has been widely applied in previous studies to quantify regional 
left ventricular myocardial function under different clinical scenarios and all the available 
evidence suggests that it is quite useful to assess left ventricular performance. However, 
despite all this knowledge on left ventricular mechanical activation, a few attempts have 
been made to quantify right ventricular dyssynchrony using these indices. In our study, 
we evaluated this index to assess RV function and use them as a marker of severity of 
pulmonary hypertension. 
 Presence of paradoxical septal motion is also a well-recognized marker of right 
ventricular deformation by either pressure or volume loads. The variability in our 
measurements of RV size, morphology, and functional performance in patients with 
variable degree of chronic pulmonary hypertension is probably due to the right 
ventricular geometric remodeling that occurs in these patients with pulmonary 
hypertension as described by Sukmawan et al. 
 Areas of further work are required in tissue Doppler imaging (TDI) which might 
be useful in the early identification of patients with sub clinical evidence of right 
ventricular dysfunction but further studies are required. In addition, the long-term effects 
of right ventricular dysfunction on morbidity and mortality as well as whether right 
ventricular resynchronization therapy that might correct right ventricular dysfunction and 
restore right ventricular function with resultant improvement of markers of disease 
severity and functional capacity also require investigation. 
 There are patients whose resting hemodynamics are normal, but in whom marked 
elevations in pulmonary pressure occur with exercise. It has been presumed that this 
represents an early stage of pulmonary vascular disease. However, as patients may have a 
hypertensive response to exercise with respect to the systemic vasculature, a similar type 
of response can occur in the pulmonary vasculature. Thus, whether exercise induced 
pulmonary hypertension represents true pulmonary vascular disease or reduced 
compliance of an otherwise normal pulmonary circulation can be difficult to ascertain 
and this is one area where further research is yet to take off. 
 
Limitations of the study: 
 Several important limitations of these studies should be acknowledged. The 
number of patients were relatively small in our study; However, even with this small 
number of patients we were able to reach our primary goal of identifying the presence of 
a statistically significant right ventricular mechanical dysfunction in patients with  
pulmonary hypertension.  
 We evaluated patients with the available investigations for PAH and they were 
incomplete. An invasive pressure measurement was not used in this study; therefore, 
assessments of right ventricular time-pressure plots, dp/dt, and pulmonary vascular 
resistance were not available to compare with our echo data.  
 We did not evaluate a number of novel measures of right ventricular function (eg, 
tricuspid annular velocity by tissue Doppler imaging, eccentricity index) and cardiac 
remodeling which are of potential value.  
 Similarly, peak systolic pulmonary arterial pressures were estimated simply based 
on tricuspid regurgitation measurements. However, this widely used Doppler-derived 
pressure estimation is well recognized and has been documented to have a good 
correlation with simultaneously obtained catheter-derived measurements; particularly in 
patients with elevated systolic pulmonary artery pressures.  
 The use of fractional area change as an index of global right ventricular systolic 
function has a limitation of being highly afterload dependent particularly in patients with 
pulmonary hypertension. This effect might be compounded by tricuspid regurgitation that 
by reducing systolic afterload augments right ventricular systolic function.  
 Nonetheless, the very consistent theme that has emerged is that echocardiographic 
evidence of right ventricular failure is an ominous finding. Additional research to further 
define the role of echocardiography in assessing prognosis and guiding therapy in 
patients with PAH would be of value.  
  
  
 
 
 
 
 
 
 
 
CONCLUSIONS 
 We conclude that our study population also had a strong female preponderance 
and had a relatively earlier onset of the disease in the 3rd or the 4th decade. 
 The study also indicated that right ventricular abnormalities occurs in patients 
with chronic idiopathic pulmonary hypertension and is strongly correlated with  right 
atrial dimensions, right ventricular size and main pulmonary artery size, which are all 
increased with increasing severity in pulmonary hypertension.   
 Other structural abnormalities include presence of pericardial effusion, 
paradoxical septal motion of IVS and pulmonary valve abnormalities (absent ‘a’ wave 
and presence of mid systolic notch or closure.  
 In addition, right ventricular functional abnormalities including RV FAC and RV 
MPI are associated with disease severity and it correlates well with pulmonary 
hypertension severity index, World Health Organization class. RV FAC decreases with 
increase in severity of pulmonary hypertension and MPI increases with increases with 
increase in PASP.   
 Right ventricular dysfunction is clearly evident even with mild elevations in the 
pulmonary artery systolic pressure and Doppler echocardiography is the test of choice in 
patients suspected to have Idiopathic Pulmonary artery hypertension. 
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APPENDIX I – PRO FORMA 
 
 
 
 
 
 
 
 
 
 EVALUATION OF PATIENTS WITH PULMONARY HYPERTENSION 
 
NAME:    AGE:     SEX:                OCCUPATION: 
 
ADDRESS:    IP/OP NO:  CD NO: 
 
 
COMPLAINTS:    WHO FUNCTIONAL CLASS -  
 
DYSPNEA    CHESTPAIN   GIDDINESS 
 
SYNCOPE    COUGH/SPUTUM  PALPITATIONS 
 
PEDAL EDEMA   HEMOPTYSIS   FATIGUE 
 
 
OTHERS: 
 
 
 
PAST HISTORY:  
SYSTEMIC HTN  DM  PUL TB BR ASTHMA 
         RHD  IHD  DRUG INTAKE 
 
PERSONAL HISTORY: SMOKING  ALCOHOL  EXPOSURE TO STD 
 
MENSTRUAL / OBSTETRIC HISTORY: 
 
FAMILY HISTORY: 
 
EXAMINATION: 
 
GENERAL EXAMINATION: 
 
VITALS : PULSE  BP  RR  TEMP 
 
CVS: JVP 
 
 
 
 
 
RS: 
 
 
 
 
ABDOMEN: 
 
 
 
 
CNS: 
INVESTIGATIONS 
 
Hb %  TC  DC    P      L        E        M     ESR   HCt   
 
BLOOD SUGAR       UREA  SERUM CREATININE 
 
LIVER FUNCTION:   THYROID FUNCTION: 
 
HIV ELISA    ANA   USG ABDOMEN 
 
CXR  :     HRCT:    
 
PULMONARY FUNCTION TESTING:    PULSEOXIMETRY 
 
 
ECG IN ALL LEADS: 
 
 
 
 
ECHOCARDIOGRAM: 
 
TTE:  
 
VALVES  RA  RV  MPA   AORTA  
  
PERICARDIAL EFFUSION  IVS PARADOXICAL MOVEMENT 
 
 
TR PG   PASP 
 
   LVEF 
 
 RV END SYST AREA  RV END DIAS AREA   
 
 RV  FRACTIONAL AREA SHORTENING 
 
RVIDd  RVIDs  ED PRPG 
 
IVCT  ICRT  ET  MPI =  IVCT+IVRT/ET 
 
 
 
PULMONARY VALVE M – MODE 
 
 
 
BUBBLE CONTRAST STUDY 
 
 
 
 
TTE: 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX II - MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
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1` Thavamani 21 F 1,2,3,5,6,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
2 Sudha 22 F 1,9 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
3 Chandra 45 F 1,2,6,9 III ANEMIA NOR NOR WNL NEG NEG + MPADIL WNL 
4 Thangaraj 25 M 1,2,6,7,8 III NOR NOR NOR WNL NEG NEG + MPA DIL WNL 
5 Jenita 18 F 1,3,9 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
6 Indira 34 F 1,2,5,6,7,8,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
7 Maragatham 36 F 1,5,7,9, II ANEMIA NOR NOR WNL NEG NEG NOR NOR WNL 
8 Radha 21 F 1,3,5,6,7,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
9 Ayyammal 16 F 1,2,3,5,6,7,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
10 Krishnan 24 M 1,3,5,6,9 IV NOR NOR NOR WNL NEG NEG + MPA DIL WNL 
11 Pandiammal 15 F 1,5,6,7,9 II ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
12 Selvakani 26 F 1,5,9 II ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
13 Jamunarani 27 F 1,2,3,5,6,8, II ANEMIA NOR NOR WNL NEG NEG + FIBROSIS WNL 
14 Indirani 30 F 1,7,3,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
15 Subramani 36 M 1,2,6,7,9 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
16 Kala 20 F 1,2,3,6,9 II ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
17 Mookammal 40 F 1,2 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
18 Jeya 32 F 1,5 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
19 Gayathri 38 F 1,2,5,8,9 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
20 Thangam 40 F 1 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
21 Chinnaponnu 23 F 1,3,5,7,8 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
22 Jhansi 32 F 1,3.,5,7 IV ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
23 Fathima 23 F 1,3,6,7,9 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
24 Gomathi 23 F 1,3,4,5,6,7,9 II ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
25 Rani 24 F 1,4,5,7 III ANEMIA NOR NOR WNL NEG NEG + MPA DIL WNL 
 
ECHOCARDIOGRAPHIC EVALUATION OF RIGHT VENTRICLE 
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1 Thavamani 5.6 34.4 3.5 2.3 MINIMAL + 167 177 24 
2 Sudha 4.7 33.6 2.9 2.5 ABSENT + 90 100 23 
3 Chandra 4.4 33 3.4 2.2 MODERATE + 100 110 27 
4 Thangaraj 6.9 36.8 4.4 2.5 ABSENT + 96 106 21 
5 Jenita 5.9 33 1.9 2.4 MINIMAL + 25 35 19 
6 Indira 5.4 36 2.7 2.4 MINIMAL + 101 111 26 
7 Maragatham 2.8 12.32 1.5 1.8 ABSENT ABSENT 36 46 17 
8 Radha 5.5 35.6 2.6 2.4 MINIMAL + 91 101 23 
9 Ayyammal 5.8 34.8 3.5 2.3 MINIMAL + 110 120 25 
10 Krishnan 4.8 34.65 2.4 2.3 MODERATE + 120 130 25 
11 Pandiammal 2.8 13.48 2.2 2.2 MINIMAL ABSENT 37 47 18 
12 Selvakani 2.9 14.3 1.5 1.8 ABSENT ABSENT 30 40 16 
13 Jamunarani 3 20.18 2.2 2.1 ABSENT + 51 61 20 
14 Indirani 5.4 33.4 2.3 2.4 MINIMAL + 104 114 24 
15 Subramani 6.9 36.7 2.1 2.2 ABSENT + 139 149 26 
16 Kala 2.5 14 2 1.9 ABSENT ABSENT 36 46 18 
17 Mookammal 4 30.86 2.7 2 ABSENT + 70 80 24 
18 Jeya 4.9 36.84 2.9 2.5 ABSENT + 100 110 25 
19 Gayathri 5.5 33.64 3.1 2.2 ABSENT + 99 109 23 
20 Thangam 4.8 28.6 3.3 2.4 MINIMAL + 75 85 25 
21 Chinnaponnu 4.8 25.6 2.8 2.3 MINIMAL + 78 88 26 
22 Jhansi 4.6 31.8 2.8 2.2 MINIMAL + 97 107 23 
23 Fathima 4 30.9 2.6 2 MINIMAL + 76 86 21 
24 Gomathi 3.9 16 2 2.1 ABSENT ABSENT 45 55 16 
25 Rani 5.4 32.9 2.6 2.3 MODERATE + 90 100 24 
 
ECHOCARDIOGRAPHIC EVALUATION OF RIGHT VENTRICLE 
(CONTINUED) 
 
S NO NAME 
RV EDA 
cm2 RV FAC % 
IVCT 
msec 
IVRT 
msec 
ET 
msec MPI a WAVE 
Mid 
systolic 
Notch 
bubble 
study 
1 Thavamani 34 10 64 121 187 0.99 NEG + NEG 
2 Sudha 34 15 88 118 289 0.71 NEG + NEG 
3 Chandra 38 15 57 71 278 0.46 NEG + NEG 
4 Thangaraj 41 21 75 50 287 0.44 NEG + NEG 
5 Jenita 28 18 75 107 225 0.81 NEG + NEG 
6 Indira 38 24 71 110 204 0.88 NEG + NEG 
7 Maragatham 29 26 78 117 287 0.68 NEG + NEG 
8 Radha 37 16 82 128 192 1.09 NEG + NEG 
9 Ayyammal 38 17 86 128 201 1.06 NEG + NEG 
10 Krishnan 35 10 66 120 187 0.99 NEG + NEG 
11 Pandiammal 30 28 80 116 292 0.67 NEG + NEG 
12 Selvakani 31 29 65 90 279 0.56 NEG + NEG 
13 Jamunarani 34 24 96 130 293 0.77 NEG + NEG 
14 Indirani 38 18 102 147 221 1.13 NEG + NEG 
15 Subramani 41 17 96 132 207 1.1 NEG + NEG 
16 Kala 32 29 62 88 274 0.55 NEG + NEG 
17 Mookammal 37 19 108 141 299 0.83 NEG + NEG 
18 Jeya 38 12 98 126 286 0.78 NEG + NEG 
19 Gayathri 38 14 80 140 274 0.8 NEG + NEG 
20 Thangam 38 18 86 136 271 0.82 NEG + NEG 
21 Chinnaponnu 39 14 94 168 295 0.89 NEG + NEG 
22 Jhansi 37 12 92 157 219 1.14 NEG + NEG 
23 Fathima 39 16 82 148 280 0.82 NEG + NEG 
24 Gomathi 34 24 67 120 299 0.63 NEG + NEG 
25 Rani 38 16 102 167 291 0.92 NEG + NEG 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
